Skip to main content

Table 1 Donor characteristics and stratification of donor and recipient rats

From: Ex vivo exposure of bone marrow from chronic kidney disease donor rats to pravastatin limits renal damage in recipient rats with chronic kidney disease

In vitro pravastatin treatment CKD ( n = 10)    
SNX (%) 66 ± 2    
Week 5 SBP (mmHg) 169 ± 28    
Week 5 urea (mmol/l) 11 ± 2    
Week 5 proteinuria (mg/24 hours) 18 ± 28    
Ex vivo pravastatin treatment experiment
Donor rats Healthy + DMEM BMC ( n = 2) Healthy + pravastatin BMC ( n = 2) CKD + DMEM BMC ( n = 4) CKD + pravastatin BMC ( n = 5)
SNX (%) 64.0 ± 6.0 69.0 ± 5.5
Week 5 SBP (mmHg) 148 ± 34 152 ± 8
Week 5 urea (mmol/l) 4.6 ± 0.01 4.1 ± 0.9 15.0 ± 4.4 15.9 ± 6.9
Week 5 proteinuria (mg/24 hours) 1.4 ± 0.4 1.8 ± 0.7 24 ± 8 49 ± 46
Recipient rats Healthy + DMEM BMC ( n = 5) Healthy + pravastatin BMC ( n = 5) CKD + DMEM BMC ( n = 10) CKD + pravastatin BMC ( n = 9)
SNX (%) 66.3 ± 1.6 66.7 ± 6.4 66.5 ± 3.5 67.6 ± 7.1
Week 5 SBP (mmHg) 156 ± 15 155 ± 16 159 ± 25 155 ± 19
Week 5 urea (mmol/l) 10.1 ± 0.9 10.3 ± 1.5 12.1 ± 3.2 10.6 ± 2.3
Week 5 proteinuria (mg/24 hours) 21.6 ± 5.6 21.9 ± 6.8 23.7 ± 17.3 22.7 ± 8.4
Systemic in vivo pravastatin treatment   
Recipient rats CKD + pravastatin ( n = 5) CKD ( n = 6)   
SNX (%) 69 ± 2 66 ± 3   
Week 5 SBP (mmHg) 158 ± 19 159 ± 10   
Week 5 urea (mmol/l) 12.7 ± 1.1 12.8 ± 1.4   
Week 5 proteinuria (mg/24 hours) 14.6 ± 2.7 16.5 ± 6.6   
  1. At 1 week before BMC or in vivo pravastatin administration (week 5 after SNX), rats were stratified based on plasma urea and SBP. Data presented as mean ± standard deviation. BMC, bone marrow cell; CKD, chronic kidney disease; DMEM, Dulbecco’s modified Eagle medium; SBP, systolic blood pressure; SNX, subtotal nephrectomy.